Genetic variations as cancer prognostic markers: Review and update

Human Mutation

Volumn 30, Issue 10, 2009, Pages 1369-1377

  Savas, Sevtap ^a,b   Liu, Geoffrey ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cancer; Candidate gene approach; Genetic variation; Genome wide association studies; Prognosis; Susceptibility; Treatment response

Indexed keywords

GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; PROGNOSIS; REVIEW;

GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; PROGNOSIS;

EID: 73349116605     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21078     Document Type: Review

References (94)

1. Andrew AS, Karagas MR, Nelson HH, Guarrera S, Polidoro S, Gamberini S, Sacerdote C, Moore JH, Kelsey KT, Demidenko E, Vineis P, Matullo G. 2008. DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered 65:105-118.
2. Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, Christiani DC, Liu G. 2008. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res 14:4010-4015.
3. Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. 2007. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res 174:19-36.
4. Bosch TM. 2008. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol 448:63-76.
5. Bouchardy C, Verkooijen HM, Fioretta G. 2006. Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer 119:1145-1151.
6. Briollais L, Wang Y, Rajendram I, Onay V, Shi E, Knight J, Ozcelik H. 2007. Methodological issues in detecting gene-gene interactions in breast cancer susceptibility: a population-based study in Ontario. BMC Med 5:22.
7. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA. 2006. Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol 60:19-37.
8. Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E. 2008. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 8:256-267.
9. Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, Foro P, Alameda F, Gayete A, Gel B, Miguel M, Albanell J, Fabregat X. 2006. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 66:1022-1030.
10. Carter NP. 2007. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 39:S16-S21.
11. Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, Chanock SJ, Habermann TM, Hartge P. 2007. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 109:5439-5446.
12. Chakravarti A. 1999. Population genetics-making sense out of sequence. Nat Genet 21:56-60.
13. Chanock SJ, Hunter DJ. 2008. Genomics: when the smoke clears. Nature 452: 537-538.
14. Chen X, Arciero CA, Godwin AK. 2006. BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance. Expert Rev Anticancer Ther 6:187-196.
15. Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, Field C, Greiner R, Hanson J, Cass CE, Parliament M. 2006. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12:2545-2554.
16. de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EG, Sijmons RH, Hofstra RM, Kleibeuker JH. 2002. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 11:1332-1352.
17. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075.
18. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, et al 2007. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087-1093.
19. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. 2008. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10:Unit 10.11.
20. Frank B, Wiestler M, Kropp S, Hemminki K, Spurdle AB, Sutter C, Wappenschmidt B, Chen X, Beesley J, Hopper JL; Australian Breast Cancer Family Study Investigators; Meindl A, and many others. 2008. Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst 100:437-442.
21. Galsky MD, Vogelzang NJ. 2007. Outcomes and prognosis in advanced renal cell carcinoma. Expert Rev Anticancer Ther 7:839-845.
22. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. 2003. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 3:291-306.
23. Gossage L, Madhusudan S. 2007. Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 11:361-380.
24. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
25. Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J. 2005. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 70:419-426.
26. Habuchi T. 2006. Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model. Future Oncol 2:233-245.
27. Hallek M, German CLL Study Group. 2008. Prognostic factors in chronic lymphocytic leukemia. Ann Oncol 19(Suppl 4), iv51-iv53.
28. Han S, Zhang HT, Wang Z, Xie Y, Tang R, Mao Y, Li Y. 2006. DNA repair gene XRCC3 polymorphisms and cancer risk: a meta-analysis of 48 case-control studies. Eur J Hum Genet 14:1136-1144.
29. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
30. Heidema AG, Boer JM, Nagelkerke N, Mariman EC, van der ADL, Feskens EJ. 2006. The challenge for genetic epidemiologists: how to analyze large numbers of SNPs in relation to complex diseases. BMC Genet 7:23.
31. Hemminki K, Bermejo JL. 2007. Constraints for genetic association studies imposed by attributable fraction and familial risk. Carcinogenesis 28:648-656.
32. Hilbig A, Oettle H. 2008. Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev Anticancer Ther 8:511-523.
33. Hiraki A, Matsuo K, Wakai K, Suzuki T, Hasegawa Y, Tajima K. 2007. Gene-gene and gene-environment interactions between alcohol drinking habit and polymorphisms in alcohol-metabolizing enzyme genes and the risk of head and neck cancer in Japan. Cancer Sci 98:1087-1091.
34. Hsieh SM, Lintell NA, Hunter KW. 2006. Germline polymorphisms are potential metastasis risk and prognosis markers in breast cancer. Breast Dis 26:157-162.
35. Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL, Das S, Dolan ME. 2008. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 68:3161-3168.
36. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D. et al 2008. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452:633-637.
37. Hunter K, Welch DR, Liu ET. 2003. Genetic background is an important determinant of metastatic potential. Nat Genet 34:23-24; author reply 25.
38. Imreh S, Klein G, Zabarovsky ER. 2003. Search for unknown tumor-antagonizing genes. Genes Chromosomes Cancer 38:307-321.
39. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. 2007. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526.
40. International HapMap Consortium; Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, and many others. 2007. A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851-861.
41. Ionita-Laza I, Rogers AJ, Lange C, Raby BA, Lee C. 2009. Genetic association analysis of copy-number variation (CNV) in human disease pathogenesis. Genomics 93:22-26.
42. Jamroziak K, Robak T. 2004. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 9:91-105.
43. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H. 2008. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108:137-149.
44. Katz DA. 2006. Overview of pharmacogenetics. Curr Protoc Hum Genet Chapter 9: Unit 9.19.
45. Kono S, Chen K. 2005. Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci 96:535-542.
46. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC. 2007. The diploid genome sequence of an individual human. PLoS Biol 5:e254.
47. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK. 2008. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:66-72.
48. Loeb LA. 1991. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075-3079.
49. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther (in press)
50. Macis D, Maisonneuve P, Johansson H, Bonanni B, Botteri E, Iodice S, Santillo B, Penco S, Gucciardo G, D'Aiuto G, Rosselli Del Turco M, Amadori M, Costa A, Decensi A. 2007. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat 106:263-271.
51. Madhusudan S, Middleton MR. 2005. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 31:603-617.
52. Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
53. Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, Matullo G. 2006. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol 164:297-302.
54. Mardis ER. 2008. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 9:387-402.
55. McCarroll SA. 2008. Extending genome-wide association studies to copy-number variation. Hum Mol Genet 17:R135-R142.
56. Mechanic LE, Luke BT, Goodman JE, Chanock SJ, Harris CC. 2008. Polymorphism interaction analysis (PIA): a method for investigating complex gene-gene interactions. BMC Bioinformatics 9:146.
57. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71.
58. Mitsudomi T, Yatabe Y. 2007. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98:1817-1824.
59. Miyagawa T, Nishida N, Ohashi J, Kimura R, Fujimoto A, Kawashima M, Koike A, Sasaki T, Tanii H, Otowa T, Momose Y, Nakahara Y, Gotoh J, Okazaki Y, Tsuji S, Tokunaga K. 2008. Appropriate data cleaning methods for genome-wide association study. J Hum Genet 53:886-893.
60. Moore JH. 2003. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 56:73-82.
61. Motsinger AA, Ritchie MD, Dobrin SE. 2006. Clinical applications of whole-genome association studies: future applications at the bedside. Expert Rev Mol Diagn 6:551-565.
62. Munro AJ, Lain S, Lane DP. 2005. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92:434-444.
63. Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P. 2007. Genetic susceptibility for breast cancer: how many more genes to be found? Crit Rev Oncol Hematol 63:125-149.
64. Paracchini V, Raimondi S, Gram IT, Kang D, Kocabas NA, Kristensen VN, Li D, Parl FF, Rylander-Rudqvist T, Soucek P, Zheng W, Wedren S, Taioli E. 2007. Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol 165:115-125.
65. Reich DE, Lander ES. 2001. On the allelic spectrum of human disease. Trends Genet 17:502-510.
66. Rochat B. 2005. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44:349-366.
67. Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N. 2005. Prognostic and predictive factors in colorectal cancer: Kirsten ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16(Suppl 4):iv44-iv49.
68. Schafmayer C, Buch S, Egberts JH, Franke A, Brosch M, El Sharawy A, Conring M, Koschnick M, Schwiedernoch S, Katalinic A, Kremer B, Folsch UR, Krawczak M, Fandrich F, Schreiber S, Tepel J, Hampe J. 2007. Genetic investigation of DNArepair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer. Int J Cancer 121:555-558.
69. Schmidt C. 2007. SNPs not living up to promise; experts suggest new approach to disease ID. J Natl Cancer Inst 99:188-189.
70. Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, Flockhart DA. 2008. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111:157-163.
71. Sharp AJ. 2009. Emerging themes and new challenges in defining the role of structural variation in human disease. Hum Mutat 30:135-144.
72. Shendure J, Ji H. 2008. Next-generation DNA sequencing. Nat Biotechnol 26:1135-1145.
73. Spitz MR, Wu X, Mills G. 2005. Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23:267-275.
74. Taioli E. 2008. Gene-environment interaction in tobacco-related cancers. Carcinogenesis 29:1467-1474.
75. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swense J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AK, Shizuya H, Eyfjord JE, Cannon-Albright L, Tranchant M, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE. 1996. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337.
76. Thomas DC. 2005. The need for a systematic approach to complex pathways in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 14:557-559
77. Thomas R, Davies N. 2007. Lifestyle during and after cancer treatment. Clin Oncol (R Coll Radiol) 19:616-627.
78. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni Jr JF, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. 2008. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40:310-315.
79. Tuzun E, Sharp AJ, Bailey JA, Kaul R, Morrison VA, Pertz LM, Haugen E, Hayden H, Albertson D, Pinkel D, Olson MV, Eichler EE. 2005. Fine-scale structural variation of the human genome. Nat Genet 37:727-732.
80. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML. 2005. Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14:2509-2516.
81. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009.
82. Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, SteinbachM, Kumar V, Mushlin R, Johnson D, MorganG. 2008.Genomic variation in myeloma: design, content, and initial application of the bank on A cure SNP panel to detect associations with progression-free survival. BMC Med 6:26.
83. Vineis P, Anttila S, Benhamou S, Spinola M, Hirvonen A, Kiyohara C, Garte SJ, Puntoni R, Rannug A, Strange RC, Taioli E. 2007. Evidence of gene gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis 28:1902-1905.
84. Voelkerding KV, Dames SA, Durtschi JD. 2009. Next-generation sequencing: from basic research to diagnostics. Clin Chem 55:641-658.
85. Wang J, WangW, Li R, Li Y, Tian G, Goodman L, Fan W, Zhang J, Li J, Zhang J, Guo Y, Feng B, Li H, Lu Y, Fang X, Liang H, Du Z, Li D, Zhao Y, Hu Y, Yang Z, Zheng H, Hellmann I, Inouye M, Pool J, Yi X, Zhao J, Duan J, Zhou Y, Qin J, Ma L, Li G, Yang Z, Zhang G, Yang B, Yu C, Liang F, Li W, Li S, Li D, Ni P, Ruan J, Li Q, Zhu H, Liu D, Lu Z, Li N, Guo G, Zhang J, Ye J, Fang L, Hao Q, Chen Q, Liang Y, Su Y, San A, Ping C, Yang S, Chen F, Li L, Zhou K, Zheng H, Ren Y, Yang L, Gao Y, Yang G, Li Z, Feng X, Kristiansen K, Wong GK, Nielsen R, Durbin R, Bolund L, Zhang X, Li S, Yang H, Wang J. 2008. The diploid genome sequence of an Asian individual. Nature 456:60-65.
86. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, He W, Chen YJ, Makhijani V, Roth GT, Gomes X, Tartaro K, Niazi F, Turcotte CL, Irzyk GP, Lupski JR, Chinault C, Song XZ, Liu Y, Yuan Y, Nazareth L, Qin X, Muzny DM, Margulies M, Weinstock GM, Gibbs RA, Rothberg JM. 2008. The complete genome of an individual by massively parallel DNA sequencing. Nature 452:872-876.
87. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. 2006. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789-3798.
88. Yamaguchi K, Arai Y, Kanda Y, Akagi K. 2001. Germline mutation of dihydropyrimidine dehydrogenase gene among a japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 92:337-342.
89. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. 2006. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 24:1761-1769.
90. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. 2005. Molecularpathological prognostic factors of gastric cancer: a review. Gastric Cancer 8:86-94.
91. Yeang CH, McCormick F, Levine A. 2008. Combinatorial patterns of somatic gene mutations in cancer. FASEB J 22:2605-2622.
92. Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. 2006. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:2239-2245.
93. Ziegler A, Konig IR, Thompson JR. 2008. Biostatistical aspects of genome-wide association studies. Biom J 50:8-28.
94. Zlobec I, Lugli A. 2008. Prognostic and predictive factors in colorectal cancer. J Clin Pathol 61:561-569.